Information for Clinicians
Transcription
Information for Clinicians Maternity Department Magnesium Sulphate for Neuroprotection in Preterm Labour Presentation Cerebral palsy is a well-recognised complication of preterm birth. While the survival of infants born preterm has improved, the prevalence of cerebral palsy has risen, with 25% of all cases of cerebral palsy occurring in infants born at less 34 weeks gestation. A number of RCTs have been performed looking at the role of magnesium sulphate (MgSO4) for neuroprotection of the premature neonate. Meta-analyses of these have shown that the use of antenatal magnesium sulphate reduces cerebral palsy and motor deficits in preterm infants, irrespective of the reasons for preterm birth. Consider for all women in labour between 24 and 30 weeks gestation. If decision is made not to give MgSO4 between 24 and 30 weeks, document reason why not on proforma. Consider for women between 23 and 24 weeks, if the couple have been counselled by the neonatal team and have decided they want ‘everything done’ if there are signs of life. Regime 1) Loading dose: Magnesium sulphate 4g given over 5 minutes Draw up 8mls (4g) of 50% magnesium sulphate and 12mls 0.9% sodium chloride (giving a total volume of 20mls) 2) Maintenance dose: Magnesium sulphate 1g/hour for 24 hours or until delivery Draw up 20mls (10g) of 50% magnesium sulphate and 30mls 0.9% sodium chloride (giving a total volume of 50mls) into a 50mls syringe. Give as IV infusion using a syringe driver, setting the infusion rate at 5mls/hour. The infusion needs to continue for 24 hours or until delivery, which ever is sooner. STOP maintenance infusion after delivery or after 24 hours, whichever is sooner NB Please complete preterm labour proforma If women require transfer to another unit, magnesium sulphate should be commenced while awaiting the transfer transport. Continue maintenance dose until ambulance arrives but DO NOT administer during transfer. Communicate treatment to team on arrival at unit Ref.: M82 – Magnesium Sulphate for Neuroprotection in Preterm Labour Approved by: Vicky Tinsley – Head of Nursing and Midwifery Author: Jo Ficquet - Consultant Obstetrician Date of Issue: 23 December 2014 © Royal United Hospital Bath NHS Trust Version: 1.0 Approved on: 04 December 2014 Review date: 04 December 2017 Page 1 of 2 Monitoring whilst on MgSO4 1. Hourly tendon reflexes. If loss of reflexes, inform senior obstetrician STOP infusion and send serum MgSO4 levels. Restart infusion at 0.5g/hour, if level < 4mmol/L or if reflexes return. 2. Monitor urine output If urine output < 100mls/4 hours or urea >10, inform senior obstetrician, check serum MgSO4 levels every 4-6 hours (therapeutic range 2-4mmol/L). If serum MgSO4 level > 4mmol/L, stop MgSO4 infusion. 3. Hourly respiratory rate (RR) and O2 saturation If RR < 14, inform senior obstetrician and stop MgSO4. Start facial oxygen at 15L/minute. Consider giving Calcium Gluconate to reverse the effects of MgSO4 rapidly. 10ml of 10% Calcium Gluconate IV over 2-5 minutes if magnesium toxicity is likely CAUTION: MgSO4 given to women taking Nifedipine may cause profound hypotension. If magnesium Sulphate is given too rapidly it can cause Ventricular Fibrillation or cardiac arrest Contraindications MgSO4 should be avoided in women with myasthenia gravis, as it may precipitate a crisis. References RCOG Scientific Advisory Committee Opinion Paper. Magnesium Sulphate to prevent cerebral palsy following preterm birth. 2011 Aug. Handbook of obstetric Medicine, Catherine Nelson-Piercy, 2005. Ref.: M82 – Magnesium Sulphate for Neuroprotection in Preterm Labour Approved by: Vicky Tinsley – Head of Nursing and Midwifery Author: Jo Ficquet - Consultant Obstetrician Date of Issue: 23 December 2014 © Royal United Hospital Bath NHS Trust Version: 1.0 Approved on: 04 December 2014 Review date: 04 December 2017 Page 2 of 2
Similar documents
Global Manganese Sulphate Market 2015 Industry Trend, Analysis, Survey and Overview
The report scrutinizes the Manganese Sulphate market and gives an intricate examination of its applications. The report includes a cost evaluation analysis of products that are available in the worldwide Manganese Sulphate market with regard to manufacturer profit margins. It helps figure out the primary driving forces of the Manganese Sulphate market in significant end-use organizations around the world. It likewise constitutes a broad investigation of the restraints on the market, business sector structure, and the business pattern of the Manganese Sulphate market. Meetings and interviews with leading market participants have been used to present primary information regarding the market. The report is characterized into numerous parts dealing with diverse aspects of the Manganese Sulphate market. This research report inspects the present situation and development prognosis of the Manganese Sulphate market around the globe during the forecasting horizon. To determine the market size, the report analyzes revenue produced in the Manganese Sulphate market worldwide alongside demonstrating the segmentation of the prime producers.
More information